MiR130A expression significantly decreased in PBMCs of ITP patients. MiR130A targeted the TGFB1 and IL18 genes. Post-treatment upregulates expression of miR130A and TGFB1, downregulates IL18 expression. This evidence concerns the gene TGFB1 and autoimmune thrombocytopenic purpura.